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Recent reports have suggested that back-
ground levels of industrial chemicals and
other environmental pollutants may play a
role in development of breast cancer in
women and decreased male reproductive
success as well as the reproductive failures of
some wildlife species (1-6). These sugges-
tions have been supported by articles in the
popular and scientific press (7-13) and by a
television documentary (14) which have
described the perils of exposure to
endocrine-disrupting chemicals such as
estrogenic organochlorine pesticides and
pollutants. During the past two decades,
environmental regulations regarding the
manufacture, use, and disposal ofchemicals
have resulted in significantly reduced emis-
sions of most industrial compounds and
their by-products. Levels of the more envi-
ronmentally stable organochlorine pesticides
and pollutants are decreasing in most
ecosystems including the industrialized areas
around the Great Lakes in North America
(15-18). Decreased levels oforganochlorine
compounds correlates with the improved
reproductive success of highly susceptible
fish-eating water birds in the Great Lakes
region (19). This article reviews key papers
that have been used to support the hypothe-
ses that environmental estrogens play a role
in the increased incidence ofbreast cancer in
women and decreased sperm counts in
males. Environmental/dietary estrogens and
antiestrogens are identified and intakes of
"estrogen equivalents" are estimated to com-
pare the relative dietary impacts of various
classes ofestrogenic chemicals.
Role ofEstrogens in Breast Cancer
and Male Reproductive Problems
Concerns regarding the role of environ-
mental and dietary estrogens as possible
contributors to the increased incidence of
breast cancer were fueled by several reports
that showed elevated levels of organochlo-
rine compounds in breast cancer patients
(20-24). The results presented in Table 1
summarize some ofthese studies that com-
pare levels of organochlorine compounds
in breast tissue or serum from breast cancer
patients and controls. Polychlorinated
biphenyls (PCBs) and 1,1-dichloro-2,2-
bis(p-chlorophenyl)ethylene (DDE) are the
two most abundant organochlorine pollu-
tants identified in all human tissues with
high frequencies. In one Scandinavian
study, levels of DDE or PCBs in adipose
tissue from breast samples were not signifi-
cantly different in breast cancer patients
compared to controls (20). In another
study in Finland, P-hexachlorocyclohexane
levels were elevated in breast cancer
patients (21); however, this compound was
not detected in adipose tissue ofsome indi-
viduals in the patient and control groups
and has a relatively low frequency ofdetec-
tion in human tissue samples. Falck and
co-workers reported that PCB levels were
elevated in mammary adipose tissue sam-
ples from breast cancer patients in
Connecticut (22). In contrast, serum levels
of DDE (but not PCBs) were significantly
elevated in breast cancer patients enrolled
in the New York University Women's
Health Study (23). DDE (but not PCB)
levels were also elevated in estrogen recep-
tor (ER)-positive but not ER-negative
breast cancer patients from Quebec com-
pared to levels in women with benign
breast disease (24). It was initially conclud-
ed by Wolff and co-workers that "these
findings suggest that environmental chemi-
cal contamination with organochlorine
residues may be an important etiologic fac-
tor in breast cancer" (22). The correlations
reported in the two U.S. studies (22,23)
heightened public and scientific concern
regarding the potential role of these com-
pounds in development of breast cancer.
These observations undoubtedly reinforced
advocacy by some groups for a ban on the
use of all chlorine-containing chemicals.
However, the proposed linkage between
PCBs and/or DDE and breast cancer is
questionable for the following reasons:
* Most studies with PCBs indicate that
these mixtures are not estrogenic, and the
weak estrogenic activity observed for
lower chlorinated PCB mixtures may be
due to their derived hydroxylated
metabolites;
* p,p'-DDE, the dominant persistent
metabolite of 1,1,1-trichloro-2,2-bis(p-
chlorophenyl)ethane (p,p'-DDT), is not
estrogenic, and levels of o,p'-DDT, the
estrogenic member ofthe DDT family, are
low to nondetectable in most environmen-
talsamples;
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Table 1. Organochlorine levels in breast cancer patients
Organochlorine compound
P-Hexachlorocyclohexane levels
elevated in breast cancer patients
(breasttissue)
DDT and PCB levels comparable in
patients and controls (breasttissue)
USA (Connecticut)
USA (New York)
USA (California)
Canada (Quebec)
PCB levels elevated in breast cancer
patients (breasttissue)
DDE levels elevated in breast cancer
patients (serum)
PCB and DDE levels comparable in
patients and controls (serum)
DDE levels increased in estrogen
receptor-positive patients (breasttissue)
Patient group (n)
Breast cancer patients (24)
Controls(16)
Breast cancer patients (18)
Controls (35)
Breast cancer patients (20)
Controls (20)
Breast cancer patients (58)
Controls (171)
Breast cancer patients (150)
Controls (150)
Breast cancer patients (9)
Controls (17)
Levels
0.13± 0.06 ppm
0.08 ± 0.03 ppm
6.47 ± 2.35 ppm PCB
5.12 ± 2.38 ppm PCB;
1.97 ± 2.24 ppm DDT
1669 ± 894 ppm PCB
1105 ±424 ppb PCB
11.0 ± 9.1 ng/mL
7.7 ± 6.8 ng/mL
4.4 ± 1.8 ppb PCB;
43.3 ± 25.9 ppb DDE
4.8 ± 2.5 ppb PCB;
43.1 ± 23.7 ppb DDE
2132 ± 2050 ppm
765 ± 527 ppm
* Epidemiology studies of individuals
occupationally exposed to relatively high
levels ofDDT (25) or PCBs (26) do not
show a higher incidence ofbreast cancer;
and
* No single class of organochlorine com-
pounds was elevated in all studies, sug-
gesting that other factors may be critical
for development ofbreast cancer.
Krieger and co-workers (27) recently
reported results from a nested case-control
study of women from the San Francisco
area which showed that there were no dif-
ferences in serum DDE or PCB levels
between breast cancer patients and control
subjects. The authors concluded that "the
data do not support the hypothesis that
exposure to DDE and PCBs increases risk
of breast cancer" (27: p. 589). This was
duly noted in Time magazine (28) by a
three-line statement in "The Good News"
section. Moreover, combined analysis of
the 6 studies which report PCB and DDE
levels in 301 breast cancer patients and
412 control patients showed that there
were no significant increases in either
DDE or PCB levels in breast cancer
patients versus controls (29).
The second major link between envi-
ronmental/dietary estrogens and human
disease was precipitated by an article pub-
lished in the Lancet, in which Sharpe and
Skakkebaek (5) hypothesized that in-
creased estrogen exposure may be responsi-
ble for falling sperm counts and disorders
of the male reproductive tract. Unlike the
proposed link between environmental
estrogens and breast cancer, this hypothesis
was not based on experimentally derived
measurements of increased levels of any
estrogenic compounds in males. Previous
studies with diethylstilbestrol, a highly
potent estrogenic drug, showed that in
utero exposure results in adverse effects in
male offspring (30), and the authors'
hypothesized that in utero exposure to
environmental/dietary estrogens may also
result in adverse effects in male offspring.
A critical experimental component sup-
porting the authors' hypothesis was their
analysis ofdata from several studies which
indicated that male sperm counts had
decreased by over 40% during the past 50
years (31). These observations, coupled
with the hypothesis that environmental
estrogens including organochlorine chemi-
cals were possible etiologic agents, were
reported with alarm in the popular and sci-
entific press (7-12) and in a BBC televi-
sion program entitled "Assault on the
Male: a Horizon Special" (14). Subsequent
and prior scientific studies have cast serious
doubts on both the hypothesis (5) and the
observed decrease in male sperm counts
(31). In 1979, Macleod and Wang (32)
reported that there had been no decline in
sperm counts, and reanalysis of the data
presented by Carlsen and co-workers
showed that sperm counts had not
decreased from 1960 to 1990 (33). Thus,
during the time in which environmental
levels of organochlorine compounds were
maximal, there was not a corresponding
decrease in sperm counts. Moreover, a
reevaluation of the sperm concentration
data was recently reported by Brownwich
et al. (34) in the British MedicalJournal,
and their analysis suggested that the
decline in sperm values in males was a
function ofthe choice ofthe normal or ref-
erence value for sperm concentrations. The
authors contend that their analysis of the
data does "not support the hypothesis that
the sperm count declined significantly
between 1940 and 1990" (34: p. 19).
These results suggest that the increasing
incidence of human breast cancer is not
related to organochlorine environmental
contaminants and that decreases in sperm
counts is highly debatable. Nevertheless,
human populations are continually exposed
to a wide variety of environmental and
dietary estrogens, and these compounds
clearly fit into the category of "endocrine
disrupters." The remainder of this article
briefly describes the different structural
classes of both environmental and dietary
estrogens and quantitates human exposures
to these compounds.
Synthetic Industrial Chemicals with
EstrogenicActivity
The estrogenic activities ofdifferent struc-
tural classes of industrial chemicals were
reported by several research groups in the
late 1960s and 1970s in which o,p'-DDT
and other diphenylmethane analogs (Fig.
1) and the insecticide kepone were charac-
terized as estrogens (35-38). Subsequent
studies have confirmed the estrogenic
activity of o,p-DDT and related com-
pounds (39) whereas the p,p'-substituted
analogs were relatively inactive (36,37). In
addition, p,p'-methoxychlor and its
hydroxylated metabolites elicit estrogenic
responses (39,40). Ecobichon and
Comeau (41) investigated the estrogenic
activities of commercial PCB mixtures
(Aroclors) and individual congeners in the
female rat uterus and reported estrogenic
responses for some Aroclors and individ-
ual congeners. Studies in this laboratory
showed that a number of commercial
PCBs did not significantly increase secre-
tion of procathepsin D, an estrogen-regu-
lated gene product, in MCF-7 human
breast cancer cells (42). It should be noted
that several hydroxylated PCBs bind to
the ER, and it is possible that para-
hydroxylated PCB metabolites may be the
active estrogenic compounds associated
with lower chlorinated PCBs (43). A
recent study reported that several addi-
tional organochlorine pesticides including
endosulfan, toxaphene, and dieldrin
exhibit estrogenlike activity and induce
proliferation ofMCF-7 human breast can-
cer cells (44).
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Figure 1. Structures of environmental estrogens (o,p'-DDT, p,p'-methoxychlor, p-nonylphenol, and
bisphenol A) and estrogenic bioflavonoids (quercetin, naringenin, and luteolin).
Other industrial chemicals or interme-
diates that have been identified as estro-
genic compounds include bisphenol-A
(Fig. 1), a chemical used in the manufac-
ture of polycarbonate-derived products
(45); phenol red, a pH indicator used in
cell culture media (46); and alkyl phenols
and their derivatives, which are extensively
used for preparation of polyethoxylates in
detergents (47,48).
Natural Estrogenic Compounds
Human exposure to estrogenic chemicals is
not confined to xenoestrogens derived
from industrial compounds. Several differ-
ent structural classes ofnaturally occurring
estrogens have been identified, including
plant bioflavonoids (Fig. 1) and various
mycotoxins including zearalenone and
related compounds (49-52). The plant
bioflavonoids include different structural
classes of compounds which contain a
flavonoid backbone: flavones, flavanones,
flavonols, isoflavones, and related conden-
sation products (e.g., coumesterol). The
estrogenic activities of diverse phytoestro-
genic bioflavonoids and mycotoxins have
been extensively investigated in in vivo
models, in vitrocell culture systems, and in
ER binding assays, and most ofthese com-
pounds elicit multiple estrogenic responses
in these assays. In addition, a number of
plant foodstuffs contain 17p-estradiol (E2)
and estrone (51,52).
Environmental and Dietary
Antiestrogens
Several different structural classes ofchem-
icals found in the human diet also exhibit
antiestrogenic activity (Fig. 2) (13).
2,3,7,8-Tetrachlorodibenzo-p-dioxin
(TCDD) and related halogenated aromat-
ics including polychlorinated dibenzo-p-
dioxins (PCDDs), dibenzofurans (PCDFs),
and PCBs are also an important class of
organochlorine pollutants that elicit a
diverse spectrum of biochemical and toxic
responses (53). These chemicals act
through the aryl hydrocarbon receptor
(AhR)-mediated signal transduction path-
way, which is thought to play a role in
most of the responses elicited by these
compounds. AhR agonists such as TCDD
have been characterized as antiestrogens
using rodent and cell models similar to
those used for determining the estrogenic
activity of dietary and environmental
chemicals. In the rodent model, TCDD
and related compounds inhibit several
estrogen-induced uterine responses includ-
ing increased uterine wet weight, peroxi-
dase activity, cytosolic and nuclear proges-
terone receptor (PR) and ER binding, epi-
dermal growth factor (EGF) receptor bind-
ing, EGF receptor mRNA, and c-fos
mRNA levels (54-58). In parallel studies,
the antiestrogenic activities ofTCDD and
related compounds have also been investi-
gated in several human breast cancer cell
lines. For example, structurally diverse
AhR agonists inhibit the following E2-
induced responses in MCF-7 human breast
cancer cells: post-confluent focus produc-
tion, secretion of tissue plasminogen acti-
vator activity, procathepsin D (52-kDa
protein), cathepsin D (34-kDa protein), a
160-kDa protein, PR binding sites, glu-
cose-to-lactate metabolism, pS2 protein
levels, and PR, cathepsin D, ER, and pS2
gene expression (42,59-65). Moreover,
TCDD inhibits formation and/or growth
ofmammary tumors in athymic nude mice
and female Sprague-Dawley rats after long-
term feeding studies or initiation with
7,12-dimethylbenzanthracene (60,66,67).
A recent epidemiology study on women
exposed to TCDD after an industrial acci-
dent in Seveso (68) reported that breast
cancer incidence was decreased in areas
with high levels of TCDD contamination
(particularly in the age class 45 to 74) and
among women living longest in an area of
low TCDD contamination. Endometrial
cancer showed a remarkable decrease, par-
ticularly in areas with medium and low
TCDD contamination (68). Thus, TCDD
and related compounds exhibit a broad
spectrum of antiestrogenic activities and,
not surprisingly, so do other AhR agonists
such as the polynuclear aromatic hydrocar-
bons (PAHs), indole-3-carbinol (IC), and
related compounds found in relatively high
levels in foodstuffs (69,70). PAHs are
found in cooked foods (71,72) and are
ubiquitous environmental contaminants.
IC is a major component of cruciferous
vegetables (e.g., brussels sprouts, cauli-
Figure 2. Structures of the environmental and
dietary antiestrogens 2,3,7,8-TCDD, indole-3-
carbinol, and benzo[a]pyrene.
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flower) and exhibits antiestrogenic and
anticancer (mammary) activities (70,73).
Bioflavonoids have been extensively
characterized as weak estrogens and there-
fore may also be active as antiestrogens at
lower concentrations. The interaction
between estrogenic bioflavonoids and E2
depends on their relative doses or concen-
trations, the experimental model, and the
specific estrogen-induced endpoint.
Markaverich and co-workers (74) reported
that the estrogenic bioflavonoids quercetin
and luteolin (Fig. 1) inhibited E2-induced
proliferation ofMCF-7 human breast can-
cer cells and E2-induced uterine wetweight
increase in 21-day-old female rats. Similar
results were also observed in this laboratory
for quercetin, resperetin, and naringenin.
For example, the bioflavonoid naringenin
inhibited estrogen-induced uterine
hyptertrophy in female rats and estrogen-
induced luciferase activity in MCF-7 cells
transfected with an E2-responsive plasmid
construct containing the 5'-promoter
region of the pS2 gene and a luciferase
reporter gene (unpublished results). In
contrast, a recent study (75) reported that
coumestrol, genistein, and zearalenone
were not antiestrogenic in human breast
cancer cells. The antiestrogenic activities of
weak dietary and environmental estrogens
require further investigation; however, it is
clear that at subestrogenic doses, some of
these compounds exhibit antiestrogenic
activities in both in vivoand in vitromodels.
Mass/Potency Balance
The uptake of environmental or dietary
chemicals that elicit common biochemical/
toxic responses can be estimated by using
an equivalency factor approach in which
estrogen equivalents (EQs) in any mixture
are equal to the sum of the concentration
of the individual compounds (ECQ) times
their potency (EPi) relative to an assigned
standard such as diethylstilbestrol (DES)
or E2 (51). The total EQs in a mixture
would be:
EQ = E ([ECi] xEP1)
A similar approach is being used to
determine the TCDD equivalents (TEQs)
ofvarious mixtures containing halogenated
hydrocarbons (76). Verdeal and Ryan (51)
have previously used this approach with
DES equivalents assuming that the oral
potency ofE2 is 15% that ofDES. Winter
(77) has estimated the dietary intake of
pesticides based on FDA's total diet study,
which includes estimates of food intakes
and pesticide residue levels in these foods.
The results presented in Table 2 summa-
rize the estimated exposure of different
groups to estrogenic pesticides. For exam-
ple, 14- to 16-year-old males were exposed
to a total of0.0416 pg/kg/day ofthe estro-
genic pesticides, DDT, dieldrin, endosul-
fan, and p,p'-methoxychlor (note: the
DDT value representsp,p'-DDE and relat-
ed metabolites, which are primarily none-
strogenic). Thus, the overall dietary intake
ofthese compounds by this age group was
2.5 pg/day.
The relative potencies of dietary and
xenoestrogens are highlyvariable. The results
of in vitro cell culture studies suggest that
estrogenic potencies ofbioflavonoids relative
to E2 are 0.001 to 0.0001 (75,78) whereas
Soto and co-workers (44) have assigned an
estrogen potency factor of0.000001 for the
estrogenic pesticides. These relative estrogen
potency factors for bioflavonoids and pesti-
cides may be lower when derived from in
vivo studies since pharmacokinetic factors
and metabolism maydecrease bioavailability.
Thus, a more accurate assessment of
dietary/environmental EQs requires further
data from dietary feeding studies that evalu-
ate these compounds using the same experi-
mental protocols.
The results in Table 3 summarize
human exposure to dietary and environ-
mental estrogens and the estimated daily
dose in terms of EQs. The relative estro-
genic intakes for various hormonal drug
therapies were previously estimated by
Verdeal and Ryan (51); the average estimat-
ed daily intake of all flavonoids in food
products was 1020 and 1070 mg/day,
Table2. Estimated dietary intake of estrogenic
pesticides by different age groups based on food
intakes and pesticide levels inthese foodstuffs
(7;)
Estimated exposure (pg/kg/day)
6-11 14-16a 60-65
Pesticide months years years
DDT(total) 0.077 0.0260 0.0103
Dieldrin 0.0014 0.0016 0.0016
Endosulfan 0.0274 0.0135 0.0210
p,p-Methoxychlor 0.0005 0.0005 0.0001
aMaximum exposure: 60 x 0.0416 = 2.5 pg/day.
(winter and summer, respectively) (52).
The results show that the estimated dietary
EQ levels of estrogenic pesticides are
0.0000025 pg/day, whereas the corre-
sponding dietary EQ levels for the
bioflavonoids are 102 pg/day. Thus, the
EQ values for the dietary intake of
flavonoids was 4 x I07 times higher than
the daily EQintake ofestrogenic pesticides,
illustrating the minimal potential of these
industrial estrogens to cause an adverse
endocrine-related response in humans.
Previous studies have also shown that
AhR agonists, such as TCDD and related
compounds, PAHs, and IC and its most
active derivative, indolo[3,2-b]carbazole
(ICZ) all inhibit E2-induced responses in
MCF-7 cells (59-65,69,70,79). At a con-
centration of 10-9 M, TCDD inhibits
50-100% ofmost E2-induced responses in
vitro in which the concentration of E2 is
10-9 M. Therefore, 1 TEQis approximate-
ly equal to 1 EQ. The estimated daily
intakes ofTCDD and related compounds,
PAHs, and ICZ (in 100 g brussels sprouts)
are summarized in Table 3. The relative
potencies of PAHs and ICZ as antiestro-
gens compared to TCDD are approximate-
ly 0.001 in MCF-7 cells (69,79). Thus, the
TEQs or antiestrogen TEQs can be calcu-
lated for the dietary intakes ofTCDD and
related organochlorines and PAHs (in all
foods) (71,72). The antiestrogen TEQs for
the three classes ofdietaryAhR agonists are
orders of magnitude higher than the esti-
mated dietary intakes of estrogenic pesti-
cide EQs. Thus, the major human intake
ofendocrine disrupters associated with the
estrogen-induced response pathways are
naturally occurring estrogens found in
foods. Relatively high serum levels ofestro-
genic bioflavonoids have also been detected
in a Japanese male population, whereas
lower levels were observed in a Finnish
group, and this is consistent with their
dietary intakes of these estrogenic com-
pounds (80). p,p'-DDE is present in
Table 3. Estimated mass balance of human exposures to environmental and dietary estrogens and anti-
estrogens (51,52,77,79)
Source Estrogen equivalents (pg/day)
Estrogens
Morning after pill 333,500
Birth control pill 16,675
Post-menopausal therapy 3,350
Flavonoids in foods (1,020 mg/day x0.0001) 102
Environmental organochlorine estrogens(2.5 x0.000001) 0.0000025
Antiestrogens TCDD antiestrogen equivalents(pg/day)
TCDD and organochlorines (80-120 pg/day) 0.000080 0.000120a
PAHs in food (1.2-5.0 x 106 pg/day; relative potency
- 0.001) 0.001200-0.0050b
Indolo[3,2-bJcarbazole in 100 g brussels sprouts 0.000250-0
(0.256-1.28 x 106 pg/day; relative potency
- 0.001)
aln moststudies, 1 nM TCDD inhibits50-100% of 1 nM E2-induced responses in MCF-7 cells(59-65);
therefore, 1 estrogen equivalent= 1 antiestrogen equivalent.
bThe antiestrogenic potencies ofPAHs(69) and indolo[3,2-b]carbazole (79) compared to E2were approxi-
mately0.001.
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human serum; however, the estrogenic
o,p'-DDE and o,p'-DDT analogs and
other weakly estrogenic organochlorine
compounds are not routinely detected in
serum samples. A recent study identified
several hydroxylated PCB congeners in
human serum. All of the hydroxylated
compounds were also substituted with
chlorine groups at both adjacent meta
positions (81). Based on results ofprevious
structure-activity studies (43) for hydroxy-
lated PCBs, these compounds would
exhibit minimal estrogenic activity; howev-
er, further studies on the activity of
hydroxylated PCBs are warranted.
Summary
The hypothesized linkage between
dietary/environmental estrogens and the
increased incidence of breast cancer is
unproven; there is a lack of correlation
between higher organochlorine levels in
breast cancer patients compared to controls
(Table 1) and the low levels oforganochlo-
rine EQs in the diet (Table 3). Higher lev-
els of bioflavonoids are unlikely to con-
tribute to increased breast cancer incidence
because these compounds and the foods
they are associated with tend to exhibit
anticarcinogenic activity (82,83). The
hypothesis that male reproductive prob-
lems and decreased sperm counts are relat-
ed to increased exposure to environmental
and dietary estrogens is also unproven. As
noted above, dietary exposure to xenoes-
trogens derived from industrial chemical
residues in foods is minimal compared to
the daily intake of EQs from naturally
occurring bioflavonoids. Moreover, there
are serious questions regarding the
decreased sperm counts reported by
Carlsen and co-workers. Reanalysis of
Carlsen et al.'s data suggests that there has
not been a decrease in sperm counts in
males over the past 30 years (33 ) and pos-
sibly over the past 50 years (34). Thus, in
response to articles in the popular and sci-
entific press such as "The Estrogen Com-
plex" (7) and "Ecocancers: Do Environ-
mental Factors Underlie a Breast Cancer
Epidemic?" (8), the results would suggest
that the linkage between dietary or envi-
ronmental estrogenic compounds and
breast cancer has not been made, and fur-
ther research is required to determine the
factors associated with the increasing inci-
dence ofthis disease.
Note added in proof A recent study (84)
reported a 2.1% decrease in sperm concen-
trations in France from 1973 to 1979.
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